Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price & Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) rose 0.61% to USD 266.11 as of September 8, 2026 at 04:16 UTC, according to Nexqual real-time market data.
ALNY last closed at USD 266.11; the session ranged USD 258.02–266.85 on volume of 1,431,221 shares. Market capitalization is —, with a 52-week range of USD 197.81–495.55 (NMS). Source: Nexqual, September 8, 2026 at 04:16 UTC.
Key Statistics (as of September 8, 2026 at 04:16 UTC)
| Price | USD 266.11 |
|---|---|
| Change | ▲ 0.61% (up) |
| Previous Close | USD 266.11 |
| Open | USD 266.11 |
| Day Range | USD 258.02 – 266.85 |
| 52-Week Range | USD 197.81 – 495.55 |
| Volume | 1,431,221 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ALNY)
Nexqual's technical model rates ALNY "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 04:16 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.61 (neutral) |
| vs SMA50 | Above (USD 258.83) |
| MACD | 2.46 (positive) |
From Alnylam Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, the United States Food and Drug Administration, or the FDA, approved our supplemental New Drug Application, or sNDA, for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
- In parallel, we advanced a proprietary technology that conjugates a sugar molecule, referred to as GalNAc, to the siRNA molecule.
- We believe this success will enable us to sustainably and organically create and commercialize transformative medicines that benefit patients around the world across a broad range of disease areas and indications.
Partnerships
- In addition, we are exploring peptide and antibody-based approaches for targeted siRNA delivery to new tissues, including as part of our collaboration with PeptiDream, Inc., which aims to discover and develop novel conjugates for targeted delivery of RNAi therapeutics to a broader range of tissues.
- We also intend to continue to build on our progress with extrahepatic delivery during 2026, advancing our CNS programs under our collaboration with Regeneron, as well as continuing to advance our other extrahepatic delivery initiatives, in support of our Alnylam 2030 goal to expand to ten tissue types by the end of 2030.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | USD 66.53 | ▼ 0.66% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 58.09 | ▼ 5.28% |
| INCY | Incyte Corporation | USD 126.75 | ▼ 1.61% |
| SRPT | Sarepta Therapeutics, Inc. | USD 22.5 | ▼ 3.06% |
| NBIX | Neurocrine Biosciences, Inc. | USD 155.64 | ▼ 1.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:16 UTC. This page is informational and not investment advice.